Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03393858|
Recruitment Status : Unknown
Verified July 2020 by Jun Ren MD, PhD, Capital Medical University.
Recruitment status was: Recruiting
First Posted : January 9, 2018
Last Update Posted : July 15, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Cancer Mesothelioma, Malignant||Drug: Anti-PD-1 antibody Biological: DC-CIK Immunotherapy Device: Thermotron RF-8EX||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective Study of Combination of Anti-PD-1 Plus Autologous DC-CIK Cell Immunotherapy and Hyperthermia for Patients With Advanced Malignant Mesothelioma|
|Actual Study Start Date :||December 1, 2017|
|Estimated Primary Completion Date :||December 31, 2021|
|Estimated Study Completion Date :||June 30, 2022|
|Experimental: Immunotherapy plus Hyperthermia||
Drug: Anti-PD-1 antibody
Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
Biological: DC-CIK Immunotherapy
Mononuclear cells were collected from 50ml peripheral blood , and cultured DC-CIK cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
Device: Thermotron RF-8EX
Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week since the 1st week of pembrolizumab for a total of 10 times.
- Progression-free survival of the participants(PFS) [ Time Frame: 24 months ]From starting date of anti-PD-1 antibody treatment until date of until the date of first documented disease progression or date of death from any cause, whichever comes first.
- Overall survival of the participants(OS) [ Time Frame: 24 months ]From starting date of anti-PD-1 antibody treatment until date of death from any cause.
- Assessment of Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) [ Time Frame: 24 months ]To assess and compare the PRO-CTCAE by patients receiving immunotherapy
- Safety (adverse events) [ Time Frame: 24 months ]Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 80 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Histological confirmed malignant mesothelioma.
- Patients who have refused a first line platinum-based chemotherapy, or patients in progression of disease after a maximum of one line of platinum-based therapy for advanced disease.
- Estimated life expectancy > 3 months.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.
- Age 18 to 80.
- Patients whose most recent major surgery or drug or radiation therapy for malignant tumors, if any, was at least 4 weeks ago at the subject enrollment.
- Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
- Adequate hematologic function, with WBC ≥ 3000/microliter, hemoglobin ≥ 9 g/dL (it is acceptable to have had prior transfusion), platelets ≥ 75,000/microliter; PT-INR <1.5 (unless patient is receiving warfarin in which case PT-INR must be <3), PTT <1.5X ULN Adequate renal and hepatic function, with serum creatinine < 1.5 mg/dL, bilirubin < 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dL), ALT and AST ≤ 2.5 x upper limit of normal.
- Participation in another clinical study with an investigational product during the last 6 weeks.
- Patients with a history of autoimmune disease, such as but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis,scleroderma, or multiple sclerosis. Autoimmune related thyroid disease and vitiligo are permitted.
- Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Patients with serious intercurrent chronic or acute illness, such as cardiac disease (NYHA class III or IV), hepatic disease, or other illness considered by the Principal Investigator as unwarranted high risk for investigational drug treatment.
- Patients with a medical or psychological impediment to probable compliance with the protocol should be excluded.
- Presence of an active acute or chronic infection including: a urinary tract infection, HIV (as determined by ELISA and confirmed by Western Blot). Patients with HIV are excluded based on immuno-suppression, which may render them unable to respond to the vaccine;patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections.
- Patients on chronic steroid therapy (or other immuno-suppressives, such as azathioprine or cyclosporin A) are excluded on the basis of potential immune suppression. Patients must have had 6 weeks of discontinuation of any steroid therapy (except that used as pre-medication for chemotherapy or contrast-enhanced studies or for acute treatment (<5 days) of intercurrent medical condition such as a gout flare) prior to enrollment.
- Pregnant and nursing women should be excluded from the protocol since this research may have unknown and harmful effects on an unborn child or on young children. If the patient is sexually active, the patient must agree to use a medically acceptable form of birth control while receiving treatment and for a period of 4 months following the last therapy. It is not known whether the treatment used in this study could affect the sperm and could potentially harm a child that may be fathered while on this study.
- Patients evidence of interstitial lung disease will be excluded.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03393858
|Contact: Jun Ren, MD,PhDfirstname.lastname@example.org|
|Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital||Recruiting|
|Beijing, China, 100038|
|Contact: Jun Ren, MD, PhD 86-10-63926317 email@example.com|
|Responsible Party:||Jun Ren MD, PhD, Director,Capital Medical University (CMU)Cancer Center, Capital Medical University|
|Other Study ID Numbers:||
|First Posted:||January 9, 2018 Key Record Dates|
|Last Update Posted:||July 15, 2020|
|Last Verified:||July 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Respiratory Tract Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Body Temperature Changes
Heat Stress Disorders
Wounds and Injuries
Physiological Effects of Drugs